Early human data hints psychedelics may calm inflammation in Parkinson's
⏮ BeforeLab studies suggested psychedelics can lower inflammation, with little human data to test it.
✅ NowResearchers now publish some of the first human data hinting at a benefit for Parkinson's patients.
In short
- Lab studies have shown psilocybin and similar psychedelics can lower inflammation.
- Researchers are publishing some of the first human data on this effect.
- The data signals potential for patients with neurodegenerative diseases such as Parkinson's.
Why the Good News Desk likes this one
Inflammation is linked to many illnesses, and lab studies have pointed to a protective effect from psychedelics. This is among the first human data suggesting the same may hold for Parkinson's and related diseases. It is an early signal, not a proven treatment, and it will need further study.
Advertisement
From NPR
Lab studies have shown that psychedelics like psilocybin can lower inflammation and may be protective for a range of illnesses. Now, researchers are publishing some of the first data in humans that signals this holds potential for patients with neurodegenerative diseases like Parkinson's disease.
Ask this story
More like this
Advertisement